Endari (glutamine)
Oral Powder In Packet (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: glutamine
Therapeutic class: Hematological Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Endari
Indications
The following indications are listed for Endari:
- Short Bowel Syndrome
Also known as: Short Gut Syndrome.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Endari 5 Gram Powder Packet | Maintenance | Take 3 packets (15 gram) mixed in 8 ounces of water, milk or apple juice by oral route 2 times per day. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| L-Glutamine 5 Gram Powder Pkt | Maintenance | Take 3 packets (15 gram) mixed in 8 ounces of water, milk or apple juice by oral route 2 times per day. |
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Disease Modifying Agents/Exagamglogene Autotemcel
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The interaction potential of disease modifying agents with exagamglogene autotemcel is unknown.(1)
CLINICAL EFFECTS: Disease modifying agents may interfere with exagamglogene autotemcel therapy.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab) at least 8 weeks prior to the start of mobilization.(1) It is recommended that patients be transfused at least 8 weeks prior to the initiation of myeloablative conditioning. At initiation of red blood cell exchange or simple transfusions, discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab).(1)
DISCUSSION: There is no experience with the use of disease modifying agents with exagamglogene autotemcel infusion.(1)
Disease Modifying Agents/Lovotibeglogene Autotemcel
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The interaction potential of disease modifying agents with lovotibeglogene autotemcel is unknown.(1)
CLINICAL EFFECTS: Disease modifying agents may interfere with lovotibeglogene autotemcel therapy.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Discontinue disease modifying therapies (e.g. voxelotor, crizanlizumab) for sickle cell disease at least 8 weeks prior to start of mobilization and conditioning.(1)
DISCUSSION: There is no experience with the use of disease modifying agents with lovotibeglogene autotemcel infusion.(1)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Neuropsychiatric disorder
More Frequent
- Acute abdominal pain
- Constipation
- Cough
- Headache disorder
- Nausea
Less Frequent
- Abdominal distension
- Abnormal hepatic function tests
- Back pain
- Chest pain
- Pain in extremities
- Vomiting
Rare or Very Rare
- Behavioral disorders
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Sickle cell disease | ||
| D57 | ICD10CM | Sickle-cell disorders |
| D57.0 | ICD10CM | Hb-SS disease with crisis |
| D57.00 | ICD10CM | Hb-SS disease with crisis, unspecified |
| D57.01 | ICD10CM | Hb-SS disease with acute chest syndrome |
| D57.02 | ICD10CM | Hb-SS disease with splenic sequestration |
| D57.03 | ICD10CM | Hb-SS disease with cerebral vascular involvement |
| D57.04 | ICD10CM | Hb-SS disease with dactylitis |
| D57.09 | ICD10CM | Hb-SS disease with crisis with other specified complication |
| D57.1 | ICD10CM | Sickle-cell disease without crisis |
| D57.2 | ICD10CM | Sickle-cell/hb-C disease |
| D57.20 | ICD10CM | Sickle-cell/hb-C disease without crisis |
| D57.21 | ICD10CM | Sickle-cell/hb-C disease with crisis |
| D57.211 | ICD10CM | Sickle-cell/hb-C disease with acute chest syndrome |
| D57.212 | ICD10CM | Sickle-cell/hb-C disease with splenic sequestration |
| D57.213 | ICD10CM | Sickle-cell/hb-C disease with cerebral vascular involvement |
| D57.214 | ICD10CM | Sickle-cell/hb-C disease with dactylitis |
| D57.218 | ICD10CM | Sickle-cell/hb-C disease with crisis with other specified complication |
| D57.219 | ICD10CM | Sickle-cell/hb-C disease with crisis, unspecified |
| D57.4 | ICD10CM | Sickle-cell thalassemia |
| D57.40 | ICD10CM | Sickle-cell thalassemia without crisis |
| D57.41 | ICD10CM | Sickle-cell thalassemia, unspecified, with crisis |
| D57.411 | ICD10CM | Sickle-cell thalassemia, unspecified, with acute chest syndrome |
| D57.412 | ICD10CM | Sickle-cell thalassemia, unspecified, with splenic sequestration |
| D57.413 | ICD10CM | Sickle-cell thalassemia, unspecified, with cerebral vascular involvement |
| D57.414 | ICD10CM | Sickle-cell thalassemia, unspecified, with dactylitis |
| D57.418 | ICD10CM | Sickle-cell thalassemia, unspecified, with crisis with other specified complication |
| D57.419 | ICD10CM | Sickle-cell thalassemia, unspecified, with crisis |
| D57.42 | ICD10CM | Sickle-cell thalassemia beta zero without crisis |
| D57.43 | ICD10CM | Sickle-cell thalassemia beta zero with crisis |
| D57.431 | ICD10CM | Sickle-cell thalassemia beta zero with acute chest syndrome |
| D57.432 | ICD10CM | Sickle-cell thalassemia beta zero with splenic sequestration |
| D57.433 | ICD10CM | Sickle-cell thalassemia beta zero with cerebral vascular involvement |
| D57.434 | ICD10CM | Sickle-cell thalassemia beta zero with dactylitis |
| D57.438 | ICD10CM | Sickle-cell thalassemia beta zero with crisis with other specified complication |
| D57.439 | ICD10CM | Sickle-cell thalassemia beta zero with crisis, unspecified |
| D57.44 | ICD10CM | Sickle-cell thalassemia beta plus without crisis |
| D57.45 | ICD10CM | Sickle-cell thalassemia beta plus with crisis |
| D57.451 | ICD10CM | Sickle-cell thalassemia beta plus with acute chest syndrome |
| D57.452 | ICD10CM | Sickle-cell thalassemia beta plus with splenic sequestration |
| D57.453 | ICD10CM | Sickle-cell thalassemia beta plus with cerebral vascular involvement |
| D57.454 | ICD10CM | Sickle-cell thalassemia beta plus with dactylitis |
| D57.458 | ICD10CM | Sickle-cell thalassemia beta plus with crisis with other specified complication |
| D57.459 | ICD10CM | Sickle-cell thalassemia beta plus with crisis, unspecified |
| D57.8 | ICD10CM | Other sickle-cell disorders |
| D57.80 | ICD10CM | Other sickle-cell disorders without crisis |
| D57.81 | ICD10CM | Other sickle-cell disorders with crisis |
| D57.811 | ICD10CM | Other sickle-cell disorders with acute chest syndrome |
| D57.812 | ICD10CM | Other sickle-cell disorders with splenic sequestration |
| D57.813 | ICD10CM | Other sickle-cell disorders with cerebral vascular involvement |
| D57.814 | ICD10CM | Other sickle-cell disorders with dactylitis |
| D57.818 | ICD10CM | Other sickle-cell disorders with crisis with other specified complication |
| D57.819 | ICD10CM | Other sickle-cell disorders with crisis, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.